The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|September 2, 2014
- Pharmaceutical Technology-09-02-2014
- Volume 38
- Issue 9
Excellims Ion-Mobility Separator Interfaces with Mass Spectrometers
The MA3100 high performance ion mobility pre-separator (HPIMS) from Excellims has been built to interface with multiple mass spectrometer (MS) product lines from Thermo Fisher Scientific.
Advertisement
The MA3100 high performance ion mobility pre-separator (HPIMS) from Excellims has been built to interface with multiple mass spectrometer (MS) product lines from Thermo Fisher Scientific. The MA3100 enhances MS technology by increasing versatility, simplifying complex spectra, and allowing targeted analysis of gas phase ions.
The HPIMS-Orbitrap MS combination delivers ultra-high-resolution separation of complex samples in both ion mobility and m/z domains and provides information about the structure and identity of molecular ions. The MA3100 is exchangeable with the current ionization sources of the MS. The technology attains high-resolution separation that has not been possible on previously existing systems and routinely performs separations with a resolving power of more than 70.
Articles in this issue
about 12 years ago
Using Ultrasonic Cleaning for Equipment and Toolingabout 12 years ago
Investigation of Various Impurities in Febuxostatabout 12 years ago
Asymmetric Synthesis Continues to Advanceabout 12 years ago
Using Quality by Design to Develop Robust Chromatographic Methodsabout 12 years ago
Waters QTof Mass Spectrometer Detects Low-Level Compoundsabout 12 years ago
Xylem Polarimeters Measure Chiral Compoundsabout 12 years ago
Extending the Scope of Pharmacovigilance Comes at a Priceabout 12 years ago
Minimizing Variation in Vial Withdrawal Practiceabout 12 years ago
The Relevance of Industry Technical Associationsabout 12 years ago
Thermo Fisher Scientific UHPLC System Improves ProductivityAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement